How honey heals wounds, fights infections and even targets cancer cells
How honey heals wounds, fights infections and even targets cancer cells
How honey heals wounds, fights infections and even targets cancer cells
Honey has been used for healing wounds and burns for thousands of years. Recent studies continue to highlight its wide range of medical benefits beyond traditional uses. Research shows honey can effectively treat both oral and genital herpes when applied directly to the skin. It also eases symptoms of psoriasis, reducing redness, scaling, and itching. For burn patients, honey speeds up healing compared to standard silver sulfadiazene dressings.
Honey’s antibacterial properties allow it to fight antibiotic-resistant infections and help heal long-term ulcers and wounds. It sterilises wounds, promotes tissue repair, and reduces pain, odour, and wound size. A 2011 Iranian study even found that honey can inhibit the growth of cancer cells.
Beyond skin and wound care, honey offers other health benefits. It has a lower glycemic index than sugar, meaning it causes a slower rise in blood sugar levels. Additionally, it improves both short- and long-term memory in menopausal and postmenopausal women. Honey also provides relief for hemorrhoid sufferers by significantly reducing pain and itching. From ancient wound care to modern medical applications, honey remains a versatile remedy. Its ability to treat infections, speed healing, and ease various conditions makes it a valuable natural treatment. These findings support its continued use in both traditional and clinical settings.
How honey heals wounds, fights infections and even targets cancer cells
Forget sugar—honey is a medical marvel. Studies show it beats antibiotics, soothes psoriasis, and may even slow tumors. Here's why doctors are taking note.
Forgotten soldier's face reconstructed decades after his death in 1945 battle
A young soldier's features emerge from history after decades of silence. Now, his family may finally find closure—if DNA can bridge the past.
Sanofi scraps $11.6B Bioverativ drug trial after CIDP treatment failure
A major setback for Sanofi's rare disease ambitions. After a failed Phase 3 study, the future of its $11.6B Bioverativ deal hangs in the balance.
How Private Data Is Solving Global Health and Social Challenges
Your data could save lives—companies are turning user information into breakthroughs in medicine, public safety, and poverty relief. But will regulation slow progress?